CAS 875446-37-0

Anacetrapib

Description:

Anacetrapib is a small molecule that belongs to the class of compounds known as CETP (cholesteryl ester transfer protein) inhibitors. It is primarily investigated for its potential in treating dyslipidemia and cardiovascular diseases by modulating lipid profiles, particularly by increasing high-density lipoprotein (HDL) cholesterol levels and reducing low-density lipoprotein (LDL) cholesterol levels. Anacetrapib is characterized by its ability to inhibit the CETP enzyme, which plays a crucial role in the transfer of cholesterol esters and triglycerides between lipoproteins. The compound has a relatively high affinity for CETP, which contributes to its efficacy. In clinical studies, Anacetrapib has demonstrated a favorable safety profile, although its long-term effects and benefits in reducing cardiovascular events are still under investigation. Its chemical structure includes a complex arrangement of functional groups that contribute to its biological activity. Overall, Anacetrapib represents a promising therapeutic approach in lipid management, although further research is needed to fully understand its clinical implications.

Formula: C₃₀H₂₅F₁₀NO₃

InChI: InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1

InChI key: InChIKey=MZZLGJHLQGUVPN-HAWMADMCSA-N

SMILES: C(C1=C(C=CC(C(F)(F)F)=C1)C2=C(OC)C=C(F)C(C(C)C)=C2)N3[C@@H](C)[C@H](OC3=O)C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4

Synonyms:

• (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4′-fluoro-2′-methoxy-5′-(1-methylethyl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone
• (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4′-fluoro-5′-isopropyl-2′-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one
• 2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4′-fluoro-2′-methoxy-5′-(1-methylethyl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl]-4-methyl-, (4S,5R)-
• Anacetrapib
• Anacetrapib (With 3 Ints.)
• Anacetrpib
• Mk 0859

Anacetrapib

CAS: 875446-37-0

(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-3-((4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methyl)-4-methyloxazolidin-2-one

Formula: C₃₀H₂₅F₁₀NO₃

Purity: 98%

Molecular weight: 637.51

Ref: IN-DG162715

(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one

CAS: 875446-37-0

Formula: C₃₀H₂₅F₁₀NO₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 637.5084

Ref: IN-DA00397D

Anacetrapib

CAS: 875446-37-0

Anacetrapib

Formula: C₃₀H₂₅F₁₀NO₃

Purity: ≥95%

Molecular weight: 637.51

Ref: 54-BUP15326

Anacetrapib

CAS: 875446-37-0

Formula: C₃₀H₂₅F₁₀NO₃

Molecular weight: 637.51

Ref: 7W-GP4221

Anacetrapib

CAS: 875446-37-0

Anacetrapib (MK-0859) inhibits rhCETP/CETP(C13S) (IC50: 7.9/11.8 nM), boosts HDL, lowers LDL cholesterol.

Formula: C₃₀H₂₅F₁₀NO₃

Purity: 98.40% - 99.87%

Color and Shape: Solid

Molecular weight: 637.51

Ref: TM-T1928

Anacetrapib

CAS: 875446-37-0

A potent inhibitor of CETP that inhibits transfer of cholesteryl esters and triglycerides. Raises HDL cholesterol levels whilst lowering LDL cholesterol. Reduces cardiovascular events in patients with atherosclerotic vascular disease that receive statin treatment.

Formula: C₃₀H₂₅F₁₀NO₃

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 637.51 g/mol

Ref: 3D-FA17899